Research Highlights

Nanocure for hepatitis, rhinitis

doi:10.1038/nindia.2012.102 Published online 17 July 2012

Researchers have designed a novel nanoparticle-based technique for treating hepatitis B and allergic rhinitis. The hepatitis B virus surface antigen (HBsAG)-loaded nanoparticles can be delivered through the nasal passage, offering an effective therapy for treating hepatitis B infection.

Infection with the hepatitis B virus (HBV) causes irritation and swelling of the liver. HBV claims many lives despite the availability of an HBV vaccine. In addition, proper vaccination requires three doses; those allergic to HBV cannot take all the doses.

To find an alternative and effective therapy, the researchers loaded trimethyl chitosan nanoparticles with HBsAG. They studied the nanoparticles' efficacy to release the antigen.

Drug release studies revealed that 93% of the HBsAG was released over a period of 43 days. Studies in female mice showed that antigen-loaded nanoparticles were highly stable and better than standard therapy techniques.

In addition, the size and surface properties of the nanoparticles can be tailored by modifying the concentration of trimethyl chitosan nanoparticles.

The researchers say that the nanoparticles can be extensively used in controlled intranasal delivery of drug molecules to treat hepatitis B. They add that these nanoparticles could also be used to treat allergic rhinitis — inflammation of the nose and eyes due to inhalation of allergens such as dust, dander and pollen.

The authors of this work are from: University of Science and Technology (UST), Gwahangno, Yuseong-gu, Daejon, Biomaterials Center, Korea Institute of Science and Technology (KIST), Hawolgok, Seoul, School of Mechanical & Advanced Materials Engineering, and Ulsan National Institute of Science and Technology (UNIST), Ulsan, Republic of Korea and Department of Pharmaceutics, Nandha College of Pharmacy, Erode, Tamil Nadu, India.


References

  1. Subbiah, R. et al. N, N, N-trimethyl chitosan nanoparticles for controlled intranasal delivery of HBV surface antigen. Carbohydr. Polymer. 89, 1289-1297 (2012) | Article |